Wednesday, August 13, 2014 11:06:50 AM
Recent Operational Highlights:
Company announced that MRI data collected on the patients in the Phase I open-label dose-escalation study of the allogeneic CDC product (CAP-1002) revealed that those patients who would be included in the Phase II clinical study by virtue of dose and tissue type compatibility, exhibited measurable improvements in ejection fraction, a global measure of the heart's pumping ability. In those patients, ejection fraction improved from an average of 38.9% at baseline to 44.1% at six-month follow-up. Measurements of infarct (scar) size, viable mass, and regional function also showed quantifiable improvements;
CNN aired a story during Sanjay Gupta's program discussing Capricor's ALLSTAR clinical trial. For the full story click here: http://www.cnn.com/2014/07/11/health/stem-cells-heart-damage/index.html?hpt=he_c1
Company entered into an Exclusive License with Cedars-Sinai Medical Center for its exosomes-related IP portfolio.
Dr. Linda Marban, Chief Executive Officer of Capricor, said, "During this past quarter we continued to execute on our strategy as we announced encouraging analysis of the MRI data at the six-month time point from our Phase I ALLSTAR trial. We are pleased with the six-month data as there are indications of both myocardial regeneration as well as possible functional improvements. We are progressing with Phase II of our ALLSTAR clinical trial and look forward to reporting on our next milestone. With our initiatives to advance our lead candidate, CAP-1002, we are clearly positioning Capricor strategically to be a leader in the cardiac therapy space."
Dr. Marban further stated, "We continue to gain recognition in the industry and have presented findings at notable symposiums and forums over the past few months. In May, we presented findings from a preclinical study on exosomes, Capricor's newly licensed platform technology, at the 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations. The preclinical study sponsored by Cedars-Sinai Medical Center showed that exosomes were able to improve cardiac function and reduce the damage resulting from a heart attack. Dr. Rachel Ruckdeschel Smith, Ph.D., Vice President of Research and Development at Capricor, outlined the study findings, which were published in the May issue of Stem Cell Reports, the official journal of the International Society for Stem Cell Research (ISSCR)."
In June, the Company announced that Dr. Rachel Ruckdeschel Smith participated in a panel discussion on the regulation of therapeutic products derived from human stem cells at the Drug Information Association (DIA) 2014 50th Annual Meeting. The forum, titled "FDA Regulation of Therapeutic Products Derived from Human Stem Cells: Successfully Navigating the Regulatory Hurdles" (#135), addressed the basic regulatory requirements for therapeutic products derived from human stem cells as biological drugs, common hurdles that arise in research and development, and options for addressing those hurdles.
In late June, during the BIO International Convention, Dr. Marban presented during a panel at the first, all-day Regenerative Medicine Forum organized by the California Institute for Regenerative Medicine (CIRM), in association with the Alliance for Regenerative Medicine (ARM) and the International Society for Stem Cell Research (ISSCR). The panel, titled "Commercializing a New Therapeutic Modality—Case Studies", was moderated by Randall Mills, President and CEO of CIRM. It focused on the importance of clinical data in bringing cell-based therapies to market, the role of clinical data at every step of the process, the importance of involving regulators early and often in the pathway to market, as well as how the players in reimbursement in this field are responding to these new approaches.
http://finance.yahoo.com/news/capricor-therapeutics-reports-second-quarter-141855371.html
Recent CAPR News
- Capricor Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 12:30:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:06:15 PM
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29 • GlobeNewswire Inc. • 02/22/2024 01:30:00 PM
- Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/16/2024 10:04:29 PM
- Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 • GlobeNewswire Inc. • 01/24/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 02:00:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:15:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:30:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 01:25:06 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 10/17/2023 08:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/13/2023 05:59:57 PM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM